MX362896B - Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. - Google Patents

Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.

Info

Publication number
MX362896B
MX362896B MX2015010619A MX2015010619A MX362896B MX 362896 B MX362896 B MX 362896B MX 2015010619 A MX2015010619 A MX 2015010619A MX 2015010619 A MX2015010619 A MX 2015010619A MX 362896 B MX362896 B MX 362896B
Authority
MX
Mexico
Prior art keywords
compounds
treatment
morpholinone
cis
cancer
Prior art date
Application number
MX2015010619A
Other languages
English (en)
Spanish (es)
Other versions
MX2015010619A (es
Inventor
D Bartberger Michael
Plake Beck Hilary
M Fox Brian
Gonzalez Lopez De Turiso Felix
Kayser Frank
C Medina Julio
H Olson Steven
Rew Yosup
M Roveto Philip
Sun Daqing
Yan Xuelei
R Degraffenreid Michael
D Julian Lisa
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2015010619A publication Critical patent/MX2015010619A/es
Publication of MX362896B publication Critical patent/MX362896B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/121,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2015010619A 2013-02-19 2014-02-18 Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. MX362896B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361766625P 2013-02-19 2013-02-19
PCT/US2014/016971 WO2014130470A1 (en) 2013-02-19 2014-02-18 Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2015010619A MX2015010619A (es) 2016-04-19
MX362896B true MX362896B (es) 2019-02-22

Family

ID=50236309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010619A MX362896B (es) 2013-02-19 2014-02-18 Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.

Country Status (7)

Country Link
US (1) US20160002185A1 (https=)
EP (1) EP2958902B1 (https=)
JP (1) JP6417338B2 (https=)
AU (1) AU2014219075C1 (https=)
CA (1) CA2901696C (https=)
MX (1) MX362896B (https=)
WO (1) WO2014130470A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
CN105358530A (zh) 2013-06-10 2016-02-24 美国安进公司 制备mdm2抑制剂的方法及其结晶形式
HRP20220718T1 (hr) 2013-11-11 2022-09-30 Amgen Inc. Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3246148A1 (de) * 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EA012181B1 (ru) 2004-10-18 2009-08-28 Амген, Инк. Соединения тиадиазола и их применение
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
EA017389B1 (ru) 2007-03-23 2012-12-28 Амген Инк. Гетероциклические соединения и их применение
WO2008118454A2 (en) 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
RS53151B (sr) 2007-03-23 2014-06-30 Amgen Inc. 3-supstituisani derivati hinolina ili hinoksalina i njihova upotreba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k)
CN101809002B (zh) * 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
WO2010083246A1 (en) 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
AU2010216239B2 (en) 2009-02-18 2012-06-14 Amgen Inc. Indole/benzimidazole compounds as mTOR kinase inhibitors
MX2011009796A (es) 2009-03-20 2011-12-14 Amgen Inc Inhibidores de la cinasa pi3.
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
MX2011012037A (es) 2009-05-13 2012-02-28 Amgen Inc Compuestos de heteroarilo como inhibidores de pikk.
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
EP2445902A2 (en) 2009-06-25 2012-05-02 Amgen, Inc Heterocyclic compounds and their uses as inhibitors of pi3k activity
CN102625799A (zh) 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
EA201270013A1 (ru) 2009-06-25 2012-06-29 Амген Инк. Гетероциклические соединения и их применение
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es) * 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.

Also Published As

Publication number Publication date
CA2901696A1 (en) 2014-08-28
EP2958902A1 (en) 2015-12-30
MX2015010619A (es) 2016-04-19
AU2014219075B2 (en) 2018-03-01
EP2958902B1 (en) 2017-11-15
CA2901696C (en) 2021-04-13
AU2014219075C1 (en) 2018-09-06
JP2016509029A (ja) 2016-03-24
AU2014219075A1 (en) 2015-08-27
JP6417338B2 (ja) 2018-11-07
US20160002185A1 (en) 2016-01-07
WO2014130470A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
PH12017502141A1 (en) Compounds and their methods of use
TN2012000559A1 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
MX2015011245A (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
MY199894A (en) Prmt5 inhibitors and uses thereof
ZA201603342B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MY191796A (en) Heterocyclic compounds as lsd1 inhibitors
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MD20160118A2 (ro) Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX2015012431A (es) Pirrol amida como inhibidores.
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch

Legal Events

Date Code Title Description
FG Grant or registration